UK product information advises that patients should: Recognise symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back, nausea, vomiting) Seek immediate medical attention if these symptoms develop Discontinue the medicine if pancreatitis is suspected Not restart the GLP-1 medicine if pancreatitis is confirmed Patients should also be aware of an increased risk of gallbladder disease (gallstones, cholecystitis) with GLP-1 medicines, which can present with similar abdominal symptoms and requires prompt medical attention
GLP-1 medications may carry risks including thyroid C-cell tumors (including thyroid cancer) and medullary thyroid carcinoma (MTC)
After one year, those veterans averaged 10% body weight loss and showed measurable improvements in body mass index (BMI), blood pressure, LDL cholesterol, triglycerides and blood sugar
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
Refunds arent available once your prescription ships to the pharmacy